// App-Quantinova.ai

613 : Effect of Tofacitinib on Efficacy and Patient-Reported Outcomes in Psoriasis Patients with Baseline Psoriatic Arthritis: A Pooled Analysis of 2 Phase 3 Studies

Researchers

Presenter

  • Herv Bachelez

Principal Investigators

  • Christopher EM Griffiths

  • Kim Papp

  • Stephen Hall

  • Joseph F Merola

  • Steven R Feldman

  • Majed Khraishi

  • Anna Tallman

  • Huaming Tan

  • Ming-Ann Hsu

Medical Centers

  • Sorbonne Paris Cité Université Paris Diderot, AP-HP Hôpital St. Louis, Paris, France

  • Dermatology Centre, University of Manchester, Manchester, United Kingdom

  • Probity Medical Research and K. Papp Clinical Research Inc, Waterloo, ON, Canada

  • emeritus research, melbourne, Australia

  • Harvard Medical School, Boston, MA

  • Internal Medicine, Wake Forest University, Winston-Salem, NC

  • Memorial University of Newfoundland, St. John's, NF, Canada

  • Pfizer Inc, New York, NY

  • Pfizer, Groton, CT

Locations

  • France

  • United Kingdom

  • Canada

  • Australia

  • United States

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • N/A

Biomarkers

  • Janus kinase

Drug/Treatment

  • Tasocitinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved